Company Email Format Management

Inozyme Pharma

Biotechnology Research 321 Summer St 59 employees

Employees: 59
Contacts: 3
Emails: 3
Phones: 2

inozyme.com LinkedIn Crunchbase

Inozyme Pharma Overview

Headquarters: 321 Summer St
Phone Number: Available in AeroLeads
Website: inozyme.com
Industry: Biotechnology Research
Employees: 59
Founded: 2016
Funding: 60.0M
Company Email: Available in AeroLeads
NAICS: Research and Development in Biotechnology (except Nanobiotechnology)

Keywords

(CMS) of a new set of ICD-10 diagnosis codes to support the classification of disorders of pyrophosphate metabolism

About Inozyme Pharma

We are a pioneering, clinical-stage biopharmaceutical company dedicated to developing innovative therapeutics for rare diseases that affect bone health and blood vessel function. Our lead candidate, INZ-701, is an ENPP1 Fc fusion protein enzyme replacement therapy (ERT) designed to increase PPi and adenosine, enabling the potential treatment of multiple diseases caused by deficiencies in these metabolites. By targeting the PPi-Adenosine Pathway, INZ-701 aims to correct pathological mineralization and intimal proliferation, addressing the significant morbidity and mortality in these devastating diseases. It is currently in clinical development for the treatment of ENPP1 Deficiency, ABCC6 Deficiency, and calciphylaxis.

Inozyme Pharma Contact Details

People in AeroLeads: 4
With contact data: 3
Email contacts: 3; 75.0% coverage
Phone contacts: 2; 50.0% coverage

Inozyme Pharma Org Chart

Sample employees and titles

Name	Title	Location	Contact
Lynne Sullivan	Chief Financial Officer at Unity	Sudbury, Massachusetts, United States	Email Phone
Yves Sabbagh, Phd	Chief Scientific Officer at Inozyme	Boston, Massachusetts, United States	Email
Herve Husson			View
Christian Phillips	Senior Vice President, Cmc	Greater Boston, United States	Email Phone